GPP Summary Sheets

The GPP Summary Sheets offer an at-a-glance look at the GPP guidelines for individuals who may not be primarily responsible for implementing GPP, but who need to understand them. They are organized according to the stages of the trial life cycle: planning, trial conduct and post-trial. Each stage outlines GPP topic areas, highlights key practices, and lists considerations for various stakeholders.

Stakeholder Interview Questions

The Stakeholder Interview Questions is a tool that is designed for trial site staff. It guides members of the research team through the process of conducting a one-on-one interview with a stakeholder. The tool provides guidance for talking with many different types of stakeholders. It can be used to evaluate the impact of stakeholder engagement efforts.

Px Wire April-June 2012, Vol. 5, No. 2

Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights from this issue include a newly debuted research timeline: “ARV-based Prevention for HIV Negative Adults.” The timeline charts the time-to-approval trajectory, showing efficacy trials, related confirmatory studies and dates of possible regulatory submission for a range of prevention options including oral PrEP with TDF, oral PrEP with TDF/FTC, vaginal and rectal formulations of tenofovir gel and the dapivirine-containing vaginal ring.

Px Wire January-March 2012, Vol. 5, No. 1

Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue identifies ten key outcomes to pursue in order to make progress in beginning to end the AIDS epidemic. This issue also covers Gilead Science’s submission to the FDA for a label change for TDF/FTC (brand name Truvada); the closure of the 1% tenofovir gel arm of the VOICE trial; new trials launched this quarter; the first meeting of Project ARM (Africa for Rectal Microbicides).

Px Wire October-December 2011, Vol. 4, No. 4

Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue includes updates on what will come next for the AIDS vaccine regimen that showed modest efficacy in the trial known as RV144; the recent VOICE trial modification; progress in demonstration projects, public health guidance and regulatory decision-making around PrEP in the United States; and, a table of early-phase studies of ARV-based prevention strategies for HIV-negative people.

Px Wire April-June 2011, Vol. 4, No. 2

Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue include a feature on new momentum to end the AIDS epidemic in light of the new HPTN 052 results showing that early ARV treatment is highly protective against transmitting HIV to one’s sexual partner. This issue also includes an abbreviated roadmap highlighting sessions on the latest biomedical prevention updates at the upcoming 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. As appears each quarter, this issue includes a center foldout poster with an updated comprehensive timeline of efficacy trials of new biomedical HIV prevention worldwide and a world map showing where various strategies are being tested.

Report of Community Consultation Among Young Women Living with HIV Currently Accessing PMTCT Services in Benue, Edo, Akwa-Ibom and Lagos States

A 7-page document developed by 2013 AVAC Fellow Oladayo Taiwo Oyelakin identifying challenges women face in access PMTCT services in Nigeria. This report used a community community consultation framework to identify barriers and provide recommendations.

Px Wire October-December 2010, Vol. 3, No. 4

Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue include an update of the ongoing discussions around the follow-up of the CAPRISA 004 trial finding that 1% tenofovir gel reduces a women’s risk of acquiring HIV by 39 percent overall and asks follow-up questions. What additional trials are being considered and why? Who will map the next steps? This issue also touches on the increasing discussions of “treatment as prevention” in reference to the possible use of antiretroviral treatment to reduce the risk of HIV transmission.

Comment Letter to Ambassador Goosby on Draft PEPFAR Country Operational Plan for Zimbabwe

A 4-page response letter developed by a coalition of civil society groups summarizing concerns and demands related to the US PEPFAR program’s 2012 Country Operating Plan. A country operating plan dictates the scope, funding levels and targets of PEPFAR programming on an annual basis.

Comment Letter to Ambassador Goosby on Draft PEPFAR Country Operational Plan for Zambia

This four-page letter on behalf of the civil society coalition in Zambia discusses recommendations for PEPFAR’s Country Operating Plan. The letter calls for stronger benchmarks and increased investment in several HIV prevention modalities.